Navigation Links
Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
Date:3/13/2008

- Pipeline Update Conference Call and Webcast on March 14 at 8:00 a.m. PDT

-

SAN DIEGO, March 13 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today reported financial results for the three months and year ended December 31, 2007.

"Our achievements in 2007 have advanced our partnered programs, while building a strong foundation for our proprietary programs. We are pursuing a number of exciting opportunities to build shareholder value and will be presenting clinical and pre-clinical data on a number of these programs throughout 2008," said Jonathan Lim, MD, Halozyme's President and CEO. "By continuing to leverage the franchises of our partners and expanding upon our broad and deep scientific expertise in the extracellular matrix, we plan to develop therapeutic and aesthetic drugs in oncology, dermatology, and metabolism."

Upcoming Scientific Data Presentations

-- American Academy of Allergy Asthma & Immunology (AAAAI) 2008 Annual

Meeting -- March 14-18th -- presentation of GAMMAGARD / Enhanze

Technology Phase I/IIa data

-- American Association of Cancer Research (AACR) Annual Meeting

2008 -- April 12-16th -- presentation of subcutaneous bisphosphonates /

rHuPH20 pre-clinical data

-- American Association of Cancer Research (AACR) Annual Meeting 2008 --

April 12-16th -- presentation of systemic PEG rHuPH20 in solid tumor

models pre-clinical data

Fourth Quarter 2007 Highlights

-- The Original Article publication of the INFUSE-LR clinical trial

results in the Jo
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
3. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
4. Halozyme Therapeutics Amends Stockholder Rights Plan
5. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
7. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Biofertilizers stimulate microbial activities in soil. These microorganisms generate ... activities in the soil or in the rhizosphere. The ... on reducing environmental pollution and on reducing the usage ... the bio fertilizers market with analysis and forecasting of ...
(Date:1/22/2015)... Shimadzu Scientific Instruments today announces the ... Offering wavelength scanning from 190 to 1,100 nm, ... in a variety of industries, including environmental, food ... enables intuitive operation, while the enhanced validation, maintenance ...
(Date:1/22/2015)... January 21, 2015 Cambridge Semantics, the leading ... today announced that 2014 was a record-breaking year across the ... of the Anzo Smart Data Platform and our Smart Data ... insights from diverse data which led to record growth for ...
(Date:1/22/2015)... San Diego, California (PRWEB) January 22, 2015 ... R Promotional Offer to their comprehensive portfolio of ... Offer allows customers to purchase a Centrifuge 5424/5424 R ... Pipette Bundle of either Eppendorf Research plus or Eppendorf ...
Breaking Biology Technology:Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 2Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 3Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 4Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2Cambridge Semantics Announces Record Results for 2014 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2
... Inverness Medical,Innovations, Inc. (Amex: IMA ) ... dated January 31, 2008 and entitled "Inverness Medical,Innovations ... and Medical Device Conference on February 5, 2008." ... Company,s presentation. The,correct time of the presentation is ...
... Calif., Feb. 1 Edwards Lifesciences,Corporation (NYSE: ... technologies to,treat advanced cardiovascular disease, is scheduled to ... Medical Device,Conference at the Grand Hyatt Hotel in ... M. Abate, Edwards Lifesciences, corporate vice president, chief,financial ...
... Inc.,(Nasdaq: VRUS ) management will be presenting at ... February 11 - 13, 2008 at the,Waldorf-Astoria Hotel in ... provide an overview of the company on Monday,February 11, ... Salon. In,addition, Dr. Michelle Berrey, Pharmasset,s Chief Medical Officer, ...
Cached Biology Technology:Edwards Lifesciences to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference 2Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th 2
(Date:1/22/2015)... Jan. 21, 2015  Analyst Report Issued by Small Cap IR. ... showed that planet-wide, transactions at merchants on the leading payment ... number of credit, debit, and prepaid cards reached 6.54 billion.  ... of fraudulent card usage in 2012, and credit and debit ...
(Date:1/22/2015)... NEW YORK , Jan. 22, 2015   EyeLock, Inc. ... announced it has appointed Steve Gerber to the ... Gerber will be responsible for leading development of mobile platforms ... 25 years of success and innovation in the semiconductor industry ...
(Date:12/22/2014)... Inc. (NASDAQ: NXTD and NXTDW) ("NXT-ID" or ... mobile commerce market, announces it has retained famous pickpocket, entertainer ... International CES debut of the Wocket™ biometric smart wallet.  ... NXT-ID booth January 6th and 7 th , 2015, demonstrating ...
Breaking Biology News(10 mins):$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4
... MD FASEB MARC (Maximizing Access to Research Careers) ... Society for the Study of Reproduction (SSR) Annual Meeting ... These awards are meant to promote the entry of ... of the basic science community and to encourage the ...
... systems work together to paralyze skeletal muscles during rapid eye ... 11 issue of The Journal of Neuroscience . The ... including narcolepsy, tooth grinding, and REM sleep behavior disorder. ... recalled dreams occur your eyes continue to move but ...
... has been awarded a grant expected to total more ... (NIH) National Institute of Allergy and Infectious Diseases (NIAID). ... vaccine against HIV and the disease it causes, AIDS. ... vaccine is urgently needed to slow and eventually eliminate ...
Cached Biology News:Study identifies how muscles are paralyzed during sleep 2Scripps Research Institute wins $77 million to develop AIDS vaccine center 2Scripps Research Institute wins $77 million to develop AIDS vaccine center 3
Rabbit polyclonal to Dishevelled 2 ( Abpromise for all tested applications). entrezGeneID: 1856 SwissProtID: O14641...
... Monoclonal Antibody, Unconjugated Applications: ... ICC: Use at an assay dependent dilution. WB: ... ug/ml, this concentration is determined using a whole ... kDa. Not tested in other applications. Optimal ...
SHP-2 Antibody...
... Neuronal (GLYT2). The antiserum has been tested ... system. The staining pattern obtained with AB1773 ... situ hybridization with probes to GLYT2 mRNA ... glycinergic neurons. Preabsorption of the antiserum with ...
Biology Products: